1.School of Pharmaceutical Science Yunnan Key Laboratory of Pharmacology for Natural Products,Kunming Medical University,Kunming 650500,China; 2.State Key Laboratory of Biotherapy,West China Hospital,Sichuan University,Chengdu 610041,China
OBJECTIVE To review the advances in non-invasive nano-sized preparations for ocular administration were systemically reviewed in this paper,which would aid in the development of non-invasive nano-sized ocular delivery system. METHODS Six preparations were classified on the basis of the properties of formulations and excipients. The quality control,transportation mechanism and safety evaluation of all the dosage forms were focused on. RESULTS AND CONCLUSION The nano-sized preparations have been grudually used in the eye disease treatment owing to their advantages including the enhancement of stability,solubility and corneal permeability,sustained ocular retention time,and improvement of the bioavailability and curative efficacy. Noninvasive administration with minimal damage to patients and side effects might have a good application prospect. However,the quality control,transportation mechanism and safety evaluation were noteworthy. It will be necessary to further develop such non-invasive nano-sized preparations for the drug delivery to ocular posterior segment.
ZHANG Ying,SONG Xiang-rong,CHEN Tong,LI Hui-li.
Recent Advances in Noninvasive Ophthalmic Drug Delivery Systems with Nanocarriers[J]. Chinese Pharmaceutical Journal, 2013, 48(17): 1429-1432 https://doi.org/10.11669/cpj.2013.17.002
[1] WAGH V D,DESHMUKH O J.Niosomes as ophthalmic drug delivery systems: A review .J Pharmacy Res,2010,3(7): 1558-1563.[2] MISHRA G P,BAGUI M,TAMBOLI V,et al.Recent applications of liposomes in ophthalmic drug delivery .J Drug Deliv,2011:863734.[3] GAN L,WANG J,JIANG M,et al.Recent advances in topical ophthalmic drug delivery with lipid-based nanocarriers.Drug Discov Today,2013,18(5-6):290-297.[4] SHAFAA M W,SABRA N M,FOUAD R A.The extended ocular hypotensive effect of positive liposomal cholesterol bound timolol maleate in glaucomatous rabbits.Biopharm Drug Dispos,2011,32(9): 507-517.[5] HABIB F S,FOUAD E A,ABDEL-RHAMAN M S,et al.Liposomes as an ocular delivery system of fluconazole: In-vitro studies .Acta Ophthalmol,2010,88(8): 901-904.[6] FUJISAWA T,MIYAI H,HIRONAKA K,et al.Liposomal diclofenac eye drop formulations targeting the retina; Formulation stability improvement using surface modification of liposomes .Int J Pharm,2012,436(6): 549-567.[7] HIRONAKA K,FUJISAWA T,SASAKI H,et al.Fluorescence investigation of the retinal delivery of hydrophilic compounds via liposomal eyedrops .Biol Pharm Bull,2011,34(6):894-897.[8] UN K,SAKAI-KATO K,OSHIMA Y,et al.Intracellular trafficking mechanism,from intracellular uptake to extracellular efflux,for phospholipid/cholesterol liposomes .Biomaterials, 2012,33(32): 8131-8141.[9] HATHOUT RANIA M,MANSOUR S,MORTADA NAHED D,et al.Liposomes as an ocular delivery system for acetazolamide: In vitro and in vivo studies .AAPS Pharm Sci Tech,2007,8(1):1. LI N,ZHUANG C Y,WANG M,et al.Low molecular weight chitosan-coated liposomes for ocular drug delivery: In vitro and in vivo studies .Drug Deliv,2012,19(1): 28-35. CHEN C W,LU D W,YEH M K,et al.Novel RGD-lipid conjugate-modified liposomes for enhancing siRNA delivery in human retinal pigment epithelial cells.Int J Nanomedicine,2011,6:2567-2580. ABDELKADER H Y,ALANY R G.Controlled and continuous release ocular drug delivery systems: Pros and cons .Curr Drug Deliv,2012,9: 421-430. GUPTA H,AQIL M,KHAR R K,et al.Biodegradable levofloxacin nanoparticles for sustained ocular drug delivery.J Drug Target,2011,19(6): 409-417. BHAGAV P,UPADHYAY H,CHANDRAN S.Brimonidine tartrate-eudragit long-acting nanoparticles: Formulation,optimization,in vitro and in vivo evaluation.AAPS Pharm Sci Tech,2011,12(4): 1087-1101. BHATTA R S,CHANDASANA H,CHHONKER Y S,et al.Mucoadhesive nanoparticles for prolonged ocular delivery of natamycin: In vitro and pharmacokinetics studies.Int J Pharm,2012,432(1-2): 105-112. BASARAN E,DEMIREL M,SIRMAGUL B,et al.Cyclosporine-A incorporated cationic solid lipid nanoparticles for ocular delivery .J Microencapsul,2010,27(1): 37-47. RUPPER A,CARDELLI J.Regulation of phagocytosis and endophagosomal trafficking pathways in dictyostelium discoideum .Biochim Biophys Acta,2001,1525(3): 205-216. CHEN Y S,ALANY R G,YOUNG S A,et al.In vitro release characteristics and cellular uptake of poly(D,L-lactic-co-glycolic acid)nanoparticles for topical delivery of antisense oligodeoxynucleotides .Drug Deliv,2011,18(7): 493-501. SABITHA K,SAJEETH C I,SANTHI K.Chitosan nanoparticles: A novel vehicle for the enhanced ocular delivery of moxifloxacin HCL .Res J Pharm(Biol Chem Sci),2012,3(2): 534-548. PANYAM J,DALI M M,SAHOO S K,et al.Polymer degradation and in vitro release of a model protein from poly(,-lactide-co-glycolide)nano- and microparticle .J Controlled Release,2003,92(1-2): 173-187. BUDHIAN A,SIEGEL S J,WINEYKI.Controlling the in vitro release profiles for a system of haloperidol-loaded PLGA nanoparticles .Int J Pharm,2008,346(1-2): 151-159. WARSI M H,CHAURASIYA A,JAIN G K,et al.Aqueous humor pharmacokinetics of dorzolamide loaded PLGA-chitosan nanoparticles by ultra performance liquid chromatography .Curr Pharm Anal,2011,7(3): 189-194. TIAN B,LUO Q,SONG S,et al.Novel surface-modified nanostructured lipid carriers with partially deacetylated water-soluble chitosan for efficient ocular delivery .J Pharm Sci,2012,101(3): 1040-1049. YONCHEVA K,VANDERVOORT J,LUDWIG A.Development of mucoadhesive poly(lactide-co-glycolide)nanoparticles for ocular application .Pharm Dev Technol,2011,16(1): 29-35. PROW TARL W.Toxicity of nanomaterials to the eye .Wires Nanomed Nanobi,2009,2(8): 317-333. LIU Z,ZHANG X,WU H,et al.Preparation and evaluation of solid lipid nanoparticles of baicalin for ocular drug delivery system in vitro and in vivo.Drug Dev Ind Pharm,2011,37(4): 475-481. KASSEM M A,ABDEL RAHMAN A A,GHORAB M M,et al.Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs.Int J Pharm,2007,340(1-2): 126-133. ADIBKIA K,OMIDI Y,SIAHI MOHAMMAD R.Inhibition of endotoxin-induced uveitis by methylprednisolone acetate nanosuspension in rabbits.J Ocul Pharmacol Th,2007,23(5): 167-175. ALI H S M,YORK P,ALI A M A,et al.Hydrocortisone nanosuspensions for ophthalmic delivery: A comparative study between microfluidic nanoprecipitation and wet milling.J Controlled Release,2011,149(2): 175-181. KALE M,SURUSE P,BODHAKE A.Ophthalmic microemulsion: A comprehensive review.Int J Pharm Bio Sci,2012,3(3): 1-13. YADAV S,KHATRI J,BHALERAO S S.Development and evaluation of an ocular anti-inflammatory microemulsion .Int J Pharm Technol,2012,4(2): 4218-4230. BENITA S,LAMBERT G.Ocular drug delivery by cationic emulsions .J Ocul Pharmacol Ther, 2004,5(11-14): 7-13. YAMAGUCHI M,UEDA K,ISOWAKI A,et al.Mucoadhesive properties of chitosan-coated ophthalmic lipid emulsion containing indomethacin in tear fluid .Biol Pharm Bull,2009,32(7): 1266-1271. LI X,ZHANG Z,LI J,et al.Diclofenac/biodegradable polymer micelles for ocular applications .Nanoscale,2012,4(15): 4667-4673. CIVIALE C,LICCIARDI M,CAVALLARO G,et al.Polyhydroxyethylaspartamide-based micelles for ocular drug delivery .Int J Pharm,2009,378(1-2): 177-186. DI TOMMASO C,VALAMANESH F,MILLER F,et al. A novel cyclosporin a aqueous formulation for dry eye treatment: In vitro and in vivo evaluation.Invest Ophthalmol Vis Sci,2012,53(4): 2292-2299. HOSNY K M.Ciprofloxacin as ocular liposomal hydrogel .AAPS Pharm Sci Tech,2010,11(1): 241-246. ZHANG H H,LUO Q H,YANG Z J,et al.Novel ophthalmic timolol maleate liposomal-hydrogel and its improved local glaucomatous therapeutic effect in vivo.Drug Deliv,2011,18(7): 502-510. SATHYAVATHI V,ABDUL HASANSATHALI A,ILAVARASAN R,et al.Formulation and evaluation of niosomal in situ gel ocular delivery system of brimonidine tartrate .Int J Life Sci Pharm Res,2012,2(1): 82-95. AMMAR H O,SALAMAL H A,GHORAB M,et al.Development of dorzolamide hydrochloride in situ gel nanoemulsion for ocular delivery .Drug Dev Ind Pharm,2010,36(11): 1330-1339.
